Cambrex Invests in New Continuous Flow Technology at its High Point, NC Facility
April 17 2018 - 8:00AM
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small
molecule innovator and generic Active Pharmaceutical Ingredients
(APIs), today announced that it has completed the installation of
multiple continuous flow reactor platforms at its High Point, NC
facility. The investment underpins Cambrex’s on-going commitment to
new technologies and aims to reinforce the company’s existing
experience in continuous flow. This latest investment in continuous
flow will focus on the rapid and successful development of
processes to supply clinical as well as commercial demand for
chemical syntheses.
The investment in developmental capabilities
builds upon the recent expansions made at the commercial-scale in
the dedicated continuous flow production unit, at the Karlskoga,
Sweden facility, which is capable of producing multiple metric tons
of high purity intermediates per annum.
The new development center at High Point will be
led by Dr. Shawn Conway, who has joined Cambrex as Director of
Engineering R&D. With extensive experience in both pilot and
commercial scale continuous processing, Dr. Conway will be
supported by a team of chemical engineers.
“We are seeing significant interest in
continuous flow development and production, predominantly from
established pharmaceutical companies looking for process
improvements in Phase II,” commented Brian Swierenga, VP,
Operations and Site Director for Cambrex High Point. He added, “We
have designed the new laboratory and GMP pilot plant with maximum
flexibility in mind, allowing us to explore the possibilities for
both new and existing production projects, either on a FTE or
custom contract basis.”
The continuous flow development center is the
latest investment at Cambrex’s High Point site which has recently
seen the completion and qualification of a new 11,000 sq.ft.
analytical laboratory and a 400 sq.ft. pilot plant expansion with a
reactor capacity of 4,000 liters.
About
CambrexCambrex Corporation is an innovative life
sciences company that provides products, services and technologies
to accelerate the development and commercialization of small
molecule therapeutics. The Company offers Active
Pharmaceutical Ingredients (APIs), advanced intermediates and
enhanced drug delivery products for branded and generic
pharmaceuticals. Development and manufacturing capabilities include
enzymatic biotransformations, high potency APIs, high energy
chemical synthesis, controlled substances and continuous
processing. For more information, please visit:
www.cambrex.com
|
|
|
Contact: |
|
Alex Maw |
|
|
Director, Marketing and
Communications |
|
|
Tel: +44 7803 443
155 |
|
|
Email:
alex.maw@cambrex.com |
|
|
|
|
|
|
|
|
|
Cambrex (NYSE:CBM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Apr 2023 to Apr 2024